Carfilzomib (Kyprolis®) in combination with daratumumab and dexamethasone (CAR+DAR+DEX). HTA ID: 20054

Assessment Status Awaiting response from Applicant
HTA ID 20054
Drug Carfilzomib (in combination with daratumumab and dexamethasone)
Brand Kyprolis®
Indication In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Assessment Process
Rapid review commissioned 08/12/2020
Rapid review completed 14/01/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of carfilzomib in combination with daratumumab and dexamethasone compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 27/01/2021
Pre-submission consultation with Applicant 12/10/2021
Full submission received from Applicant 17/07/2023
Preliminary review sent to Applicant 05/03/2024
NCPE assessment re-commenced 12/04/2024
Factual accuracy sent to Applicant 07/06/2024